MultiVu Video Feed: The Food and Drug Administration Approves the Reintroduction of TYSABRI(R) (Natalizumab) for the Treatment of Relapsing Forms of Multiple Sclerosis

Monday June 5, 2:57 pm ET

NEW YORK, June 5 /PRNewswire/ -- Biogen Idec (Nasdaq: BIIB - News) and Elan Corporation, plc (NYSE: ELN - News) today announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for the reintroduction of TYSABRI® (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the frequency of clinical relapses. The companies anticipate that TYSABRI will be available for commercial use in July.

The FDA granted approval for reintroduction based on the review of TYSABRI clinical trial data; revised labeling with enhanced safety warnings; and a risk management plan (TOUCH Prescribing Program) designed to inform physicians and patients of the benefits and risks of TYSABRI treatment and minimize potential risk of progressive multifocal leukoencephalopathy (PML). Because of the increased the risk of PML, TYSABRI monotherapy is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate MS therapies.

                               SATELLITE FEEDS:

               Monday, June 5th, 2006       Monday, June 5th, 2006
               3:30 PM - 3:45 PM ET         6:15 PM - 6:30 PM ET
               IA 6                         IA 6
               Transponder 15               Transponder 16
               C-Band                       C-Band
               Downlink: 4000 Vertical      Downlink: 4020 Horizontal

                          Tuesday, June 6th, 2006
                          3:00 AM - 3:15 AM ET
                          IA 6
                          Transponder 15
                          C-Band
                          Downlink: 4000 Vertical

            Preview and access this video on Pathfire DMG: 24030
 Search within the PR Newswire or MultiVu section by story ID # 24030 or by
                                  headline
 For technical assistance call Pathfire Customer Care at 1-888-345-0489 or
                        e-mail support@pathfire.com

   FORMAT:  News Package With Extra Soundbites and B-roll.

NEWS: FDA Approves Reintroduction of TYSABRI® For Relapsing Forms of Multiple Sclerosis

ADDITIONAL RESOURCES: Video, contact information and more available at http://www.prnewswire.com/broadcast/24030/consumer.shtml.

    SOUNDBITES:
   * Sonda Lawson, Director of MS Clinical Research and Services at The
     Michigan Institute for Neurological Disorders, Patient
   * Howard Rossman, M.D., Medical Director of the Michigan Institute For
     Neurological Disorders
   * Celeste Markey, MS Patient

B-ROLL INCLUDES: ***TYSABRI Infusion Footage***Patient Lifestyle Footage***Clinic Examination Footage***Product Shot***

VIDEO PROVIDED BY: Biogen Idec and Elan

---

Source: Biogen Idec; Elan Corporation, plc